| Accession | Title | Series type(s) | Organism(s) | Samples | GDS | Supplementary | Contact | Release date |
|---|---|---|---|---|---|---|---|---|
 Filter
|
Homo sapiens
|
Jianxin Wang
|
||||||
| GSE249537 |
Extracellular niche and tumor microenvironment enhance the impact of KRAS inhibitors in pancreatic cancer models [CRISPR]
|
|
10 | Jianxin Wang | Jan 24, 2024 | |||
| GSE249539 |
Extracellular niche and tumor microenvironment enhance the impact of KRAS inhibitors in pancreatic cancer models [RNA-seq]
|
|
12 | Jianxin Wang | Jan 24, 2024 | |||
| GSE249541 |
Extracellular niche and tumor microenvironment enhance the impact of KRAS inhibitors in pancreatic cancer models.
|
|
47 | Jianxin Wang | Jan 24, 2024 | |||
| GSE199919 |
RB-loss determines selective resistance and novel vulnerabilities in breast cancer modelsRB loss
|
|
11 | Jianxin Wang | Jun 13, 2022 | |||
| GSE275628 |
TAS-102, Irinotecan, and Bevacizumab in Pre-treated Metastatic Colorectal Cancer (TABAsCO), A Phase II Clinical Trial. ClinicalTrials.gov NCT04109924
|
|
34 | Jianxin Wang | Aug 26, 2024 |
